Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches

Area of Science:

• Microbiology and Infectious Diseases
• Pharmacology and Drug Development
• Nanotechnology

Background:

• Tuberculosis (TB) continues to cause significant mortality worldwide, exacerbated by multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
• The rise in HIV cases and latent TB infections further complicates global TB control efforts.
• Existing treatment challenges underscore the urgent need for novel therapeutic strategies and drug discovery.

Purpose of the Study:

• To provide a comprehensive overview of the current landscape of tuberculosis (TB) drug development.
• To discuss the historical progression and current status of anti-TB drugs, including those in clinical and preclinical trials.
• To highlight the challenges and bottlenecks in TB drug development and explore potential solutions, including nanosciences.

Main Methods:

• Literature review of existing research on tuberculosis (TB) and anti-TB drug development.
• Analysis of the mechanisms of action for various classes of anti-TB drug candidates.
• Exploration of the potential applications of nanosciences in combating TB.

Main Results:

• Several novel drug classes are under development, including fluoroquinolones, rifamycins, oxazolidinones, diarylquinolines, nitroimidazoles, and benzothiazinones.
• Drugs like bedaquiline, sutezolid, PA824, and BTZ043 show promise in combating resistant TB strains.
• Nanoscience offers potential for improved drug delivery and efficacy in TB treatment.

Conclusions:

• The development of new anti-TB drugs is critical to address the growing threat of drug resistance.
• A diverse range of novel molecules and therapeutic approaches are in development pipelines.
• Integrating nanosciences may offer innovative solutions to overcome current challenges in TB therapy.